Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №10 (2024) > How to treat not causing harm?

How to treat not causing harm?

Ekaterina V. Kulchavenya

For citation:


  • Abstract
  • About the Author
  • References

Abstract

Difficulty selecting drug therapy for patients with intercurrent diseases is demonstrated, selection of drugs exerting the narrowest spectrum of undesirable effects in cases of compulsory polypharmacy is substantiated. In the cohort of patients with chronic cystitis there are patients with overactive bladder (OAB) occurring under the guise of cystitis and female patients with comorbid OAB and cystitis. Obviously, standard therapy for cystitis does not ensure restoration of normal urination in such patients. Thus, restoration of normal urination in patients with OAB can be considered as the cystitis prevention and treatment method and vice versa. When treating multimorbid and elderly patients with OAB,  trospium chloride is the drug of choice, since it has a number of unique chemical and pharmacokinetic properties: trospium chloride is a positively charged quaternary ammonium compound, which does not allow it to cross the BBB; trospium chloride is not metabolized by the cytochrome P450 system, which significantly reduces the possibility of drug interaction; trospium chloride is excreted unchanged in urine as an active parent compound, ensuring extra local activity to achieve rapid and prolonged effect. Chronic prostatitis is another common disease in outpatient urology practice. The term “chronic prostatitis” (CP), like the term “chronic pelvic pain syndrome” includes a number of various symptomatic models, and many aspects of CP still remain a mystery. The association of oxidative stress with inflammation and inflammatory responses is beyond doubt. It has been proven that inflammatory macrophages release the glutathionylated peroxiredoxin-2 that later acts as a “danger signal”, triggering production of tumor necrosis factor alpha. It is emphasized that damage to DNA resulting primarily from oxidative stress is the main cause of sperm dysfunction. However, oxidative stress is caused by modifiable factors, and the use of simple measures, such as taking the antioxidant complex supplement, can reduce its severity. The following substances have antioxidant properties: vitamins А, Е, and С; minerals zinc, copper and selenium; glutathione, carnitine, N-acetylcysteine, coenzyme Q10, carnosine, L-arginine, lycopene, resveratrol, myo-inositol, folic acid, α-lipoic acid, pentoxifylline, quercetin, etc. We recommend to pay attention to the Selzinc® Plus antioxidant vitamin mineral complex containing both non-enzymatic low molecular weight antioxidants (α-tocopherol (47 mg), β-carotene (4.8 mg), ascorbic acid (180 mg)) and minerals (zinc (7.2 mg) and selenium (50 µg)). 
Keywords: cystitis, lower urinary tract infections, overactive bladder, chronic cystitis, m-anticholinergics, trospium chloride, spasmex, antioxidants, selzinc.

About the Author

Ekaterina V. Kulchavenya 1

1 Novosibirsk State Medical University, Novosibirsk, Russia; Privolzhsky Research Medical University, Nizhny Novgorod, Russia; Medical center "Avicenna", Novosibirsk, Russia

References

1. Кульчавеня Е.В., Холтобин Д.П., Шевченко С.Ю. и др. Частота хронического простатита в структуре амбулаторного урологического приема. Экспериментальная и клиническая урология. 2015;(1):16-9.
Kulchavenya E.V., Kholtobin D.P., Shevchenko S.Yu. et al. The frequency of chronic prostatitis in the structure of outpatient urological admission. Experimental and clinical urology 2015;(1):16-9 (in Russian).
2. Wagenlehner F, Wullt B, Ballarini S et al. Social and economic burden of recurrent urinary tract infections and quality of life: a patient web-based study (GESPRIT). Expert Rev Pharmacoecon Outcomes Res 2018;18(1):107-17. DOI: 10.1080/14737167.2017.1359543
3. Öztürk R, Murt A. Epidemiology of urological infections: a global burden. World J Urol 2020;38(11):2669-79. DOI: 10.1007/s00345-019-03071-4
4. Гаджиева З.К. Инфекция мочевыводящих путей и гиперактивный мочевой пузырь. Есть ли связь? Урология. 2024;(1):153-61. DOI: 10.18565/urology.2024.1.153-161
Gadzhieva Z.K. Urinary tract infection and overactive bladder. Is there a connection? Urology. 2024;(1):153-61. DOI: 10.18565/urology.2024.1. 153-161 (in Russian).
5. Кузьмин И.В., Слесаревская М.Н., Ромих В.В. Гиперактивный мочевой пузырь, воспаление и инфекция мочевыводящих путей: патогенетические параллели Урологические ведомости. 2024;14(1):65-79. DOI: 10.17816/uroved627461
Kuzmin I.V., Slesarevskaya M.N., Romikh V.V. Overactive bladder, inflammation and urinary tract infection: pathogenetic parallels. Urological reports. 2024;14(1):65-79. DOI: 10.17816/uroved627461 (in Russian).
6. Peyronnet B, Mironska E, Chapple C et al A Comprehensive Review of Overactive Bladder Pathophysiology: On the Way to Tailored Treatment. Eur Urol 2019;75(6):988-1000. DOI: 10.1016/j.eururo.2019.02.038
7. Ke QS, Lee CL, Kuo HC. Recurrent urinary tract infection in women and overactive bladder – Is there a relationship? Tzu Chi Med J 2020;33(1):13-21.
8. Pearce MM, Hilt EE, Rosenfeld AB et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. mBio 2014;5(4):e01283-14. DOI: 10.1128/mBio.01283-14
9. Khan Z, Healey GD, Paravati R et al. Chronic Urinary Infection in Overactive Bladder Syndrome: A Prospective, Blinded Case Control Study. Front Cell Infect Microbiol 2021 Sep 30;11:752275. DOI: 10.3389/fcimb.2021. 752275
10. Старцев А.И., Докукина Т.В., Голубева Т.С. и др. Показатели заболеваемости деменцией при болезни альцгеймера и сосудистой деменцией в республике Беларусь. Вопросы организации и информатизации здравоохранения. 2018;4(97):53-8.
Startsev A.I., Dokukina T.V., Golubeva T.S. et al. Incidence rates of dementia in Alzheimer’s disease and vascular dementia in the Republic of Belarus. Issues of organization and informatization of healthcare. 2018;4(97):53-8 (in Russian).
11. Geoffrion R. Urogynaecology committee. Treatments for overactive bladder: focus on pharmacotherapy. J Obstet Gynaecol Can 2012;34(11):1092-101. DOI: 10.1016/S1701-2163(16)35440-8
12. Кульчавеня Е.В., Брижатюк Е.В. Туберкулез мочевого пузыря: диагностика и лечение. Урология. 2006;(3):61-5.
Kulchavenya E.V., Brigatyuk.V. Tuberculosis of the bladder: diagnosis and treatment. Urology. 2006;(3):61-5 (in Russian).
13. Рейхруд Т.А., Кульчавеня Е.В., Мышкова Е.П. и др. Туберкулез и беременность. Акушерство и гинекология. 2017;(10):124-9. DOI: 10.18565/aig.2017.10.124-129
Reichrud T.A., Kulchavenya E.V., Myshkova E.P. et al. Tuberculosis and pregnancy. Obstetrics and gynecology 2017;10:124-9. DOI: 10.18565/aig.2017.10.124-129 (in Russian).
14 Ivchenko A, Bödeker RH, Neumeister C, Wiedemann A. Anticholinergic burden and comorbidities in patients attending treatment with trospium chloride for overactive bladder in a real-life setting: results of a prospective non-interventional study. BMC Urol 2018;18(1):80.
15. Кульчавеня Е.В., Холтобин Д.П. Гиперактивный мочевой пузырь у сложного пациента: какой препарат выбрать? Урология. 2021;(1):120-5. DOI: 10.18565/urology.2021.1.120-125
Kulchavenya E.V., Brigatyuk.V. Hyperactive bladder in a difficult patient: which drug should I choose? Urology. 2021;(1):120-5. DOI: 10.18565/urology.2021.1.120-125 (in Russian).
16. Кульчавеня Е.В., Трейвиш Л.С., Баранчукова А.А. Особенности лечения нарушений мочеиспускания у женщин в постменопаузе. Урология. 2021;(6):72-7. DOI: 10.18565/urology.2021.6.72-77
Kulchavenya E.V., Trayvish L.S., Baranchukova A.A. Features of the treatment of urinary disorders in postmenopausal women. Urology. 2021;(6):72-7. DOI: 10.18565/urology.2021.6.72-77 (in Russian).
17. Выборнов С.В., Асфандияров Ф.Р., Сеидов К.С., Круглов В.А. Антиоксиданты в лечении пациентов с воспалительными заболеваниями мужской репродуктивной системы, осложненными экскреторно-токсической формой бесплодия. Экспериментальная и клиническая урология. 2018;(3):74-8.
Vybornov S.V., Asfandiyarov F.R., Seidov K.S., Kruglov V.A. Antioxidants in the treatment of patients with inflammatory diseases of the male reproductive system complicated by an excretory toxic form of infertility. Experimental and clinical urology. 2018;(3):74-8 (in Russian).
18. Брижатюк Е.В., Шевченко С.Ю. Влияние образа жизни больного хроническим простатитом на ее качество. Вестник урологии. 2020;8(3):13-7. DOI: 10.21886/2308-6424-2020-8-3-13-17
Brizhatyuk E.V., Shevchenko S.Yu. The influence of the lifestyle of a patient with chronic prostatitis on its quality. Bulletin of Urology. 2020;8(3):13-7. DOI: 10.21886/2308-6424-2020-8-3-13-17 (in Russian).
19. Кульчавеня Е.В., Осадчий А.В. Эффективность сперматопротективной терапии на основе Селцинка плюс у больных туберкулезом предстательной железы. Consilium Medicum. 2016;18(7):22-6. DOI: 10.26442/2075-1753_2016.7.22-26
Kulchavenya E.V., Osadchy A.V. The effectiveness of spermatoprotective therapy based on Selcink plus in patients with tuberculosis of the prostate gland. Consilium Medicum. 2016;18(7):22-6. DOI: 10.26442/2075-1753_2016.7.22-26 (in Russian).
20. Сивков А.В., Ощепков В.Н., Евдокимов В.В. и др. Эффективность и безопасность препарата Селцинк Плюс у пациентов с хроническим неинфекционным простатитом и нарушениями фертильности Consilium Medicum. 2011;13(7):5-9.
Sivkov A.V., Oschepkov V.N., Evdokimov V.V. et al. The efficacy and safety of Selcink Plus in patients with chronic non-infectious prostatitis and fertility disorders Consilium Medicum. 2011;13(7):5-9 (in Russian).

For citation:Kulchavenya E.V. How to treat not causing harm? Clinical review for general practice. 2024; 5 (10): 107–112 (In Russ.). DOI: 10.47407/kr2024.5.10.00503


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru